RetinAI, Novartis, and Sankara remain vulnerable to competitors

AI has become the state-of-the-art method for vision tasks such as image classification and deep learning algorithms have been used successfully in ophthalmology to detect diseases such as diabetic retinopathy, age-related macular degeneration, and glaucoma.

In December of 2020, RetinAI announced a multiyear collaboration with Novartis Pharma in order to apply RetinAI’s artificial intelligence solutions to more and larger projects in ophthalmology. Since this partnership began, the companies have developed AI designed to investigate Optical Coherence Tomography images and assess the images for disease indicators. Additionally, in 2021, Sankara deployed its AI-based tool to assist physicians with diagnosing diabetic retinopathy.

However, although these companies are revolutionizing ocular diagnostic medicine, none have patent assets in the sector. Therefore, similar to last week’s insight about Google’s new artificial intelligence dermatology tool, the lack of patent assets leaves these companies vulnerable to competitors.

MicrosoftIBMMeditecPsomagenTopcon, and Vizzario have all secured patent assets in this sector that give them leverage over RetinAI, Novartis, and Sankara’s technology. The most notable of these are Microsoft’s patent for forecasting eye condition progression for patients and IBM’s patent for early prediction of age-related macular degeneration.

To keep up with emerging patent trends and see which companies continue to develop their patent portfolios check out the AI Biotech Patent Forecast®!